Effects of cox inhibitors on bone and tendon healing

Experimental studies of fracture healing, tendon healing and tendon-to-bone healing in the rat

Sigbjørn Dimmen

Institute for Surgical Research, Rikshospitalet, Oslo University Hospital
Orthopaedic Department, Ullevaal, Oslo University Hospital
Faculty of Medicine, University of Oslo

Thesis

Oslo, Norway 2010
Conclusions

• There is a negative effect of short-term administration of the cox-2 inhibitor parecoxib on fracture healing.

• There is a negative effect of short-term administration of the cox-2 inhibitor parecoxib and the conventional NSAID indomethacin on the earlier fracture healing process.

• There is a negative effect of short-term administration of the cox-2 inhibitor parecoxib and the conventional NSAID indomethacin on tendon healing.

• There is a negative effect of short-term administration of the cox-2 inhibitor parecoxib and the conventional NSAID indomethacin on tendon-to-bone healing.
Introduction

Cox inhibitors, both conventional NSAIDs and the specific cox-2 inhibitors, have commonly been used in musculoskeletal trauma and orthopedic surgery to reduce inflammatory responses and pain. These drugs are demonstrated to be efficient in the treatment of postoperative pain related to orthopedic surgery. However, concerns in using cox inhibitors in orthopedic fracture treatment have been raised due to their possible negative effect on fracture healing, and similar concerns have also been expressed regarding soft tissue healing.

The present thesis was prepared on the basis of the continuing discussion in the literature to elucidate the effects of cox inhibitors on fracture healing, tendon healing and tendon-to-bone healing.

Tissue healing

Bone

Traditionally, the healing of fractures has been divided into primary (direct) and secondary (indirect) fracture healing. Primary healing occurs in presence of anatomic reduction and rigid fixation. The majority of fractures heal by secondary healing, and this process has been divided into five stages; hematoma formation, inflammation, formation of soft callus, formation of hard callus and remodeling. During recent years, researchers have increasingly focused on the cell and molecular biology of fracture healing. Distinct responses of fracture healing take place in all four components involved at the injury site; the bone marrow, cortex, periosteum and external soft tissue.

Overall, fracture healing is a complex physiological process, and remains to a great extent an unknown cascade of complex biological events. Intracellular and extracellular molecular signaling are involved, and systemic and local factors like growth factors, hormones and cytokines interact at the fracture site. The process involves thousands of activated genes; the transcriptional steps are required for the regulation of the inflammatory response, chondrogenesis, osteogenesis and remodeling. The initial days after fracture represent the fundamental stage of the healing process, and the role of the inflammation is important in initiating the repair process.

Tendon

Normal tendon healing occurs in three overlapping phases. In the initial inflammatory phase, erythrocytes and inflammatory cells invade the site of injury. This phase lasts for 4 to 7 days, and is followed by the proliferative phase. Within the first week, fibroblasts fill the gap between the two tendon stumps, and capillaries grow into the gap. Collagen synthesis may begin as early as on the third day and continues over the next 5 to 6 weeks. In the following remodeling phase, consolidation of the tissue from cellular to fibrous develops and at last maturation of the fibrous tissue to a more scar-like tendon tissue occurs. Collagen fibers near the tendon ends begin to align along the long axis of the tendon, and collagen organization and cross-linking continue over the course of a year. However, after 6 months, there are usually only minimal histological differences between repair tissue and normal tissue.

Tendon-to-bone

Tendons are attached to bone through either fibrocartilaginous or fibrous insertions. In fibrocartilaginous insertions, typically seen where tendons attach to epiphyses, a characteristic 4-layered architecture is seen, consisting of tendon, non-mineralized fibrocartilage, mineralized fibrocartilage and bone. Fibrous insertions characteristically occur where tendons and ligaments are attached to diaphyseal bone either as a periosteal insertion where the collagen fibers penetrate the bone indirectly via the periosteum, or as a bony insertion where they attach directly to the bone without showing fibrocartilage layers. When healing occurs between tendon and bone inside a bone tunnel, a fibrous insertion develops. Initially, a fibrous layer of scar tissue separates tendon and bone and inflammatory cells are also present. Later, collagen fibers from the cancellous bone protrude through this fibrous tissue directly into the tendon in the presence of predominantly fibroblastic cells and less inflammatory cells. In a dog model there is continuity between the collagen fibers of the tendon and the surrounding trabecular bone after 26 weeks, indicating that a complete healing has occurred.

In contrast, in another study in rats, a tendon was mechanically healed in a bone tunnel after 6 weeks. When testing, the specimens ruptured at the muscle-tendon junction rather than the healing tendon-to-bone junction, maybe due to an intact suture supporting the reattachment during testing and not the healing alone. Most likely more time is needed before solid healing is also achieved in rats, but the time aspect remains uncertain.

Prostaglandin and cyclooxygenase

Prostaglandin (PG) was first identified by von Euler in 1936. Piper and Vane asserted in 1971 that PGs was released from different tissues after stimulation of a PG biosynthesis.

In the acute inflammation cascade the synthesis of PGs begins with release of arachidonate from membrane phos-
pholipids. Cyclooxygenase (cox), previously named prostaglandin endoperoxide synthase (PGHS), is the key enzyme required for the conversion of arachidonic acid to prostaglandin 29. Other eicosanoids, like thromboxane, are also synthesized by cox, and a total number of more than 100 related substances derived from arachidonic acid are recognized 30. Three cox isoforms have been identified, cox-1 31, cox-2 32 and cox-3 33. The cox-3 isoform is detected in the central nervous system and is sensitive to inhibition by acetaminophen/paracetamol; the role of the cox-3 is far from elucidated 30. The cox-1 enzyme is produced constitutively in nearly all tissues and is mainly responsible for the biosynthesis of PGs involved in homeostatic regulation. Cox-2 is inducible and primarily involved in producing PGs in response to a wide spectrum of environmental insults and internal stimuli; i.e. in an acute inflammation 34.

After a fracture, the release of prostaglandins increase 35. Dead cells in the area results in an aseptic inflammatory response, and without this inflammation the bone resorption and formation necessary for healing cannot occur adequately 36. PGs have a direct effect on bone resorption through increased osteoclastic activity 37-41. Furthermore, PGs increase the replication and differentiation of the osteoblasts, resulting in enhanced bone formation 38,41. Thus, PGs are partly responsible for ensuring the balance between bone resorption and bone formation 34,42,43.

It is demonstrated that cox-2 plays a critical role in bone resorption 44, and induction of cox-2 in osteoblasts is reported to be essential to the acute stress response in a bone remodeling system 45. Furthermore, cox-2 is demonstrated to be specifically essential for fracture healing 46 and required for both intramembranous and endochondral bone formation 47. The inflammation is present in the early phase after fracture, and the cox-2 mRNA level shows peak expression during the first 2 weeks and a return to basal levels by 3 weeks. Similarly, it is demonstrated that cox-2 regulates early stages of myofiber growth during muscle regeneration 48, and that cox-2 is important in the muscle healing process 49.

**Cox inhibitors**

Cox inhibitors are used in the treatment of inflammation and pain. Conventional cox inhibitors, the non steroid anti inflammatory drugs (NSAIDs), inhibit both the cox-1 and cox-2 enzymes. The newer, selective cox-2 inhibitors mainly target the cox-2 enzyme.

Vane demonstrated in 1971 that the therapeutic effects of aspirin and indomethacin were due to inhibition of the synthesis of prostaglandins 50. Other NSAIDs were developed, including naproxen, ibuprofen, piroxicam, diclofenac, ketorolac and others. After the discovery of the cox-2 enzyme 32, and the fact that cox-2 was inducible 51, the individual variations of activity against cox-1 and cox-2 between the different NSAIDs were elucidated 52,53. Two selective cox-2 inhibitors were introduced in 1999, celecoxib and rofecoxib, they are potent inhibitors of cox-2 and weaker inhibitors of cox-1 30. Other cox-2 inhibitors have later been developed, such as valdecoxib, parecoxib, etoricoxib and others.

Cox inhibitors show a wide range of side effects, with variations between conventional cox inhibitors and cox-2 inhibitors, and also between the different conventional cox inhibitors and the different cox-2 inhibitors. This variation is probably due to the cox inhibitors variable potency against cox-1 and cox-2. It has been demonstrated that piroxicam and indomethacin show high gastrointestinal toxicity 54, and these drugs have a much higher potency against cox-1 than cox-2 55.

Fewer serious gastrointestinal adverse events with rofecoxib compared to naproxen were reported 56. Furthermore, the same study demonstrated that the incidence of myocardial infarctions was higher in patients who were administered rofecoxib, leading to the withdrawal of rofecoxib from the market. Cannon et al. demonstrated, however, that the rate of thrombotic cardiovascular events in patients with arthritis and treated with etoricoxib was similar to those in patients on diclofenac, when considering patients after long-term use of these drugs 57. Warner and Mitchell also guard against the increasingly prevalent idea that conventional cox inhibitors have inherently lower cardiovascular risks than the specific cox-2 inhibitors 58.

**Use of cox inhibitors in orthopedic surgery and trauma**

Cox inhibitors have been demonstrated to be efficient in the treatment of postoperative pain related to orthopedic surgery 1-7, and are widely in use to reduce opioid analgesia. In a review article the authors conclude that opioid consumption in all included trials was reduced on average by 35 % with cox-2 inhibitors 59. However, it was not possible to demonstrate any definite clinically beneficial effect with reduced opioid related adverse events like nausea.

Cox-2 inhibitors are advantageous in relation to surgery as they do not impair the platelet activation and aggregation which is mediated by cox-1 through the generation of thromboxane A2 60. Therefore they are safer concerning perioperative bleedings 61-65. Cox-2 inhibitors are at least as effective against postoperative pain as the conventional cox inhibitors 66-68, and should probably be the drug of choice when cox inhibitors are indicated.

Recently 21 peer-reviewed articles and abstracts concerning the perioperative use of NSAIDs and cox-2 inhibitors were retracted after having been identified as fraudulent 69-72. These retractions also compromise every systematic review, meta-analysis and editorial that have included these fabricated data, and among other conclusions following these retractions, it was concluded that there is no longer evidence supporting the preemptive effect of NSAIDs and cox-2 inhibitors when administered before surgery 73.

Due to this, the entire area of perioperative pain management should be reassessed.
**Effects of cox inhibitors on tissue healing**

*Cox inhibitors effects on fracture healing*

It is well documented in experimental studies that cox inhibitors have a negative effect on bone metabolism and impair fracture healing, both for conventional cox inhibitors like indomethacin, ibuprofen, naproxen, ketorolac, diclofenac, and also for newer specific cox-2 inhibitors like celecoxib, rofecoxib, etodolac, valdecoxib, and parecoxib. The cox-2 enzyme is critically involved in bone repair and required for both intramembranous and endochondral bone formation. This indicates that inhibition of the cox-2 enzyme is responsible for the impaired healing.

Even short-term administration of cox inhibitors have a negative effect on the healing process, indicating that the initial period after a fracture is important. However, the negative effect seems to be reversible after short-term administration.

Clinical evidence of the effects on bone healing is sparse. In a retrospective study on femoral shaft fractures a marked association between nonunion and the use of NSAIDs after injury was noted. Delayed healing was also observed in patients administered NSAIDs and whose fractures had united.

A good clinical trial on this subject is a study published by Burd, which observed a patient population randomly allocated into groups of indomethacin treatment, radiation or no treatment to evaluate heterotopic ossification after surgical treatment of acetabular fracture. These patients had concomitant long bone fractures distributed equally into the three groups, and there was a significant increase of nonunion in patients who received indomethacin compared to those who did not receive indomethacin. There were no nonunions in the acetabular fractures, however, indicating that fractures known to be vulnerable to nonunion or delayed union are exposed when administered cox inhibitors, but not fractures with fewer healing problems in mainly trabecular bone. This is further illustrated by two studies published showing no effect of cox inhibitors on fractures of the distal radius (Colles’ fracture) and nonunions following distal fractures of the radius are extremely rare, and only a few cases have been reported in the literature.

*Cox inhibitors effects on tendon healing*

The effects of cox inhibitors on tendon healing are less studied than fracture healing. It has been demonstrated that ibuprofen produced a deleterious effect on tendon rupture strength and impaired the healing process. In the healing process, tendon cells migrate to the injury site, proliferate and synthesize collagen. In an experimental study, celecoxib inhibited both the tendon cell migration and proliferation. It has also been demonstrated that indomethacin might have a negative effect on tendon healing in the early proliferative phase, but might be beneficial in the remodeling phase. This is in accordance with the findings in Virchenko’s study, where parecoxib had a negative effect in the early phase of tendon healing, but during remodeling inflammation appeared to have a negative influence. This is probably the reason why indomethacin and celecoxib was reported to increase the failure stress in a healing tendon. In that study the cox inhibitors were administered until termination after 14 days. This is probably far into the remodeling phase in rats, when cox inhibitors may have a positive influence on healing. It is still unclear, however, how long these healing processes take in human compared to rat, but Virchenko suggests that a week in rats corresponds to a month in humans.

*Cox inhibitors effects on tendon-to-bone healing*

To achieve normal tendon-to-bone healing, bone ingrowth and mineralization are required. To our knowledge, only 2 experimental studies on cox inhibitors’ effects on tendon-to-bone healing have been previously published. Cohen’s study demonstrated that indomethacin and celecoxib impaired rotator cuff tendon-to-bone healing, confirmed with both mechanical testing and histological analysis. The cox inhibitors appeared to inhibit the formation and maturation of collagen at the tendon attachment site. In Ferry’s study they also demonstrated a detrimental effect on the healing strength at the patellar tendon insertion, when celecoxib, valdecoxib and piroxicam were administered; no effect was seen with ibuprofen and naproxen. A detrimental effect on collagen production was seen with celecoxib, valdecoxib, piroxicam and naproxen, but not with ibuprofen. They suggested that the different absorption and metabolism between the drugs and the uncertainties of oral drug administration could explain the different inhibition effects between the conventional cox inhibitors.

*Cox inhibitors effects on heterotopic ossification*

Heterotopic ossification (HO), also named ectopic bone formation, is a common complication following implant surgery, i.e. hip replacement surgery. The pathogenesis of HO is unclear, but trauma to the soft tissue appears to induce the process. The process is similar to that observed during fracture healing with an initial acute inflammation. Cox inhibitors have been widely used to prevent HO. Several review articles have been published during recent years confirming preventive effects, including a Cochrane review. The effect is best documented in total hip replacements, but cox inhibitors are also effective in preventing HO in acetabular fractures and after spinal injuries. Indomethacin has been the drug of choice, but other conventional cox inhibitors have been shown to be effective as well.

During the last years, the specific cox-2 inhibitors have also proved to be as effective as conventional cox inhibitors. And indeed, findings do indicate that the formation of HO is mainly mediated by cox-2.

Traditionally, cox inhibitors have been administered for a period of 4-6 weeks postoperatively in prevention of HO,
but short-term administration for 2–10 days also seems to be effective 118,123,124.

**Cox inhibitors effects on spinal fusion**

Indomethacin has been shown to inhibit posterior spinal fusions in the rat 125 and the rabbit 87. Celecoxib delayed allograft healing and incorporation in femoral shaft fractures in mice 126. In a retrospective clinical study published on spinal fusion, a higher incidence of nonunion was found in patients receiving ketorolac, and an even higher incidence if they also smoked cigarettes 127. Corresponding findings were observed in another study, but here the patients used cox inhibitors over a longer period 128. In contrast, ketorolac did not increase the incidence of nonunions in adolescents 129. However, the incidence of nonunions in adolescents was as low as 2.5%, indicating a substantial healing potential in young patients.

**Cox inhibitors effects on implant incorporation**

Several studies have demonstrated impaired bone ingrowth into porous implants 130–132, and it is also demonstrated that cox-2 activity is essential for the osseointegration in a titanium implant 133. The detrimental effect of perioperatively administered indomethacin on bone ingrowth was transient in yet another study 134, but the model was unloaded. In a clinical setting, restricted weight-bearing might be prudent.

It is suggested that the most important cause of implant loosening is osteolysis due to an inflammatory reaction to particulate wear debris, in which particles of polyethylene, metal, and bone cement debris are phagocytosed by macrophages. This process is shown to be cox-2 dependent, and cox-2 contributes to accelerated bone loss in wear debris-induced osteolysis. It is also demonstrated that a cox-2 inhibitor inhibited titanium-induced PGE₂ production and inflammation, and due to these effects, cox-2 inhibitors might reduce bone loss in inflammation-induced bone disease 135. Accordingly, cox inhibitors may have a positive effect on the prevention of implant loosening. However, titanium wear debris will probably appear some time after the implantation of an implant. Due to this, administration of cox inhibitors should perhaps be avoided during the first days postoperatively to secure bone ingrowth, but administered after some time to prevent wear debris osteolysis.

In a clinical study, there were no radiographical differences after 6 years in patients administered indomethacin 100 mg daily in 6 weeks to prevent HO after cementless total hip prosthesis 136. Equivalently, the migration of cementless acetabular implants were not different in patients administered with indomethacin 100 mg daily in 2 weeks to prevent HO compared with patients receiving irradiation or the control group 137. However, in yet another clinical study on HO prevention after cemented hip arthroplasty, there were significantly more revisions due to aseptic loosening or periprosthetic fractures in patients administered ibuprofen 400 mg 3 times daily in 7 or 21 days compared to the placebo 138.

Recently it was demonstrated that celecoxib did not affect fixation in total knee replacement after 2 years 139. However, the prostheses were fixed with bone cement. Due to this, fixation of the implants did not depend on bone ingrowth, and the cox-2 inhibitor could safely be administered.

**Cox inhibitors effects on ligament healing**

The literature supports neither a positive nor negative influence of cox inhibitors on ligament healing. In one study it was demonstrated that piroxicam increased the early healing strength of the medial collateral ligament (mcl) in rats after short-term administration, but the final strength was not affected 140. In another study, the short-term administration of celecoxib impaired the early healing of mcl in rats 141. Short-term administration of a specific cox-1 inhibitor (SC-560) did not have any influence on healing of the mcl in rats 142. When comparing short-term administration of different cox inhibitors, other analgesics and a placebo, piroxicam was found to increase the healing strength of mcl in rats, but no difference in healing strength was found in rats administered with naproxen, rofecoxib, butorphanol (opiate) or acetaminophen 143. In rabbits, no difference in strength was demonstrated in the healing of mcl after 2 weeks of ibuprofen administration 144.

It is demonstrated in several studies that early motion improves the healing of the mcl 145–147. Treatment with cox inhibitor after mcl injury could, due to the analgesic effect, improve early motion, and may thereby influence healing. However, it is demonstrated that analgesics in general do not appear to affect ligament healing in rats 143. Uncertainties related to oral administration, absorption of the drugs and degree of cox inhibition might explain some of the diversity in experimental findings.

**Cox inhibitors effects on muscle healing**

Piroxicam might delay muscle regeneration in the early period 148. It has been demonstrated, using both pharmacological and genetic approaches that the cox-2 pathway regulated early stages of myofiber growth during muscle regeneration, and that a cox inhibitor reduced the number of myoblasts 48. Also, the cox-2 pathway plays an important role in muscle healing, and prostaglandins are key mediators of the cox-2 pathway 149.

Other studies suggest a negative effect on myofiber growth with both decreased myonuclear addition and decreased inflammation, and a direct regulation of muscle cell activity by cox-2. Cox-2 activity is important for myofiber growth in multiple physiological conditions 49.
General discussion

Ethical considerations

All four studies in this thesis are experimental studies in rats. Unfortunately, neither in vitro models to study the healing processes, nor human methods to test mechanical properties exist. Thus, animal studies were chosen. All studies were performed using animal models previously published from our group \(^{150-154}\), and the number of animals was kept to a minimum in accordance with the statistical power analysis. Specially educated personnel supervised the animals on a daily basis. All experiments conformed to and were consented by the Norwegian Council of Animal Research Code for the Care and Use of Animals for Experimental Purposes.

In pharmaceutical studies one should be aware of the ethical considerations related to connections between scientists and the pharmaceutical industry. There may be a great divergence between the companies’ aims and those of science \(^{155}\). Large amounts of money are involved; in the year 2000 nearly 45 million prescriptions were written for celecoxib and rofecoxib in the United States alone \(^{156}\). Scientists behind many studies received large grants or funds from the pharmaceutical companies, or they may even be employees of those companies. Recently it was revealed that at least 21 of anesthesiologist Scott Reuben’s published papers were pure fiction (Scientific American, March, 2009 (http://www.sciam.com/article.cfm?id=a­medical­madoff­anesthestesiologist­faked­data)), and these studies have been retracted \(^{69-72}\).

The work of this thesis was supported by grants from Smith & Nephew Research Fund, Nordic Medical Supply Arthroscopy Fund and the Norwegian Olympic Center.

Methodological considerations

Experimental animals

Rats of the Wistar strain were used. In male rats, there is a quick metabolism of the two cox-2 inhibitors rofecoxib and celecoxib \(^{157,158}\). This might also apply to parecoxib, the cox-2 inhibitor used in our studies. To ensure a half-life comparable to that in humans, we only used female rats in the studies. Rats have been widely used in orthopedic experimental research, and their anatomy and physiology are well known. The bone remodeling in rats is comparable to that in humans \(^{159}\), and tendon healing and tendon-to-bone healing are also assumed to resemble human healing. However, the healing processes seem to be much faster in rats \(^{159}\), and 2 weeks is therefore a considerable healing time in rat models \(^{103}\). The onset of puberty in female rats is at 5 weeks of age \(^{160}\). In rat adulthood, each month is roughly equivalent to 2.5 human years \(^{161}\). However, these time perspectives do not necessarily represent corresponding times in rats and humans regarding the tissue healing processes.

Our animal laboratories are modern with excellent facilities. In all studies the animals were kept in pairs in wire-topped plastic cages with free access to tap water and standard laboratory rodent food (with 1.1% calcium, 0.8 % phosphorus and 1500 IU/kg vitamin D<sub>3</sub>) in a 12-hour light and 12-hour dark cycle. The animals were taken care of by educated and professional personnel. In all studies the animals gained weight during the course of the experiments.

Drug administration

For surgery and bone density measurements the animals were anesthetized with a combination of Hypnorm (fluanisone 5 mg/mL, fentanyl citrate 0.1575 mg/mL) and Dormicum (midazolam 2.5 mg/mL). Temgesic (buprenorphin 0.3mg/mL) 0.01ml/100 g body weight was given subcutaneously as analgesic. The animals were killed with a phenobarbital overdose. Parecoxib (Dynastat, Pfizer, Pharmacia Europe EEIG, Kent, Great Britain) is a potent and selective inhibitor of cox-2 \(^{162,163}\) for parenteral use and therefore ideal for administration in animal studies. Parecoxib is also claimed to become the anti-inflammatory drug of choice for parenteral treatment of post-operative pain in the future \(^{164-166}\). Indomethacin (Confortid, Dumex-Alpharma A/S, Copenhagen, Denmark) is primarily a cox-1 inhibitor \(^{55}\) and the best documented conventional cox inhibitor to delay fracture healing \(^{46,75,76}\). This drug is also available for parenteral use, and is thus suitable for animal studies.

The cox inhibitors were administered ip twice daily to ensure the best absorption and sufficient blood concentrations. An even better method to ensure constant plasma concentration of the drugs, would be to use implantable minipumps \(^{93}\). Parecoxib was administered in a dose of 0.05 mg/100 g body weight in the morning and the evening for 7 days, the first injection immediately before surgery. Indomethacin was administered in a dose of 0.0625 mg/100 g body weight at the same time points. These doses are equivalent to human doses. The half-life of cox-2 inhibitors is shown to be 3–5 times higher in male rats compared to humans \(^{157,158,167,168}\), whereas the half-life in female rats and humans are comparable \(^{157,168}\). Thus we chose to administer human doses, corrected for weight, to female rats.

Comparing the effects of indomethacin with parecoxib, however, is associated with some uncertainties due to the rats’ different metabolism of different cox inhibitors. Any demonstrated difference could be dose related, and not drug related. Plasma concentration measurements may have increased the value of the drug comparisons.
Tibial fracture model
In study I and II the right hindlimb of the rats was fractured using a specially designed fracture forceps \(^{169}\). Prior to this, a reaming of the medullary canal was performed using an 18 G cannula (BD venflon Pro 18 GA 1.26 IN (1.3 × 32 mm)). Post fracture, this cannula stabilized the tibia, together with a smaller cannula (Braun Sterican 19 G/1.5 IN (1.20 × 40 mm)) passing through the largest one and advancing down towards the ankle joint. On the innermost level, the stylet of a 22 G spinal cannula (Braun Spinocan 22 G x 3 ½ IN (0.73 × 88 mm)) was inserted. This stylet was kept inside the medullary canal when the tibia was fractured to facilitate the reduction of the fracture during fixation \(^{152}\). The rotation was only secured by the press fit effect of the cannulas. Rotational instability was not a problem in this model, neither in these studies nor in previous studies from our group.

Tendon rupture model
In Paper III the Achilles tendon of the right hindlimb was cut, and a 3 mm long segment was removed. The tendon was left unsutured \(^{104}\). The plantaris tendon was left intact, but carefully dissected free from the healing Achilles tendon before mechanical testing. Whether maintaining the plantaris tendon leads to more or less weight bearing may be questioned. The plantaris tendon is strong in rats, and can take over some function after the Achilles tendon is injured. However, even if the animals are allowed full weight bearing, they generally protect their operated hind limb. Due to this, we believe that keeping the plantaris tendon intact may result in increased loading of the operated limb, and tendon loading has been shown to increase PG release, DNA and protein synthesis \(^{102}\). This factor might have significance for the healing after treatment with cox inhibitors. In cox inhibitor treated animals this would probably not have the same importance due to the impaired PG production, but in placebo animals increased PG could possibly increase healing, resulting in larger differences between the groups. The animals in our study were allowed full weight bearing with no immobilization. All tendons healed. No time study was performed to elucidate if the healing tendons would have regained full strength during the later course of healing.

Tendon-to-bone model
In study IV, no previous model in the rat was available, to our knowledge. We therefore developed our own model in a pilot study to confirm the surgical technique and decide the time point of termination. In the pilot study we killed the animals and did the dissections and mechanical testing at three time points; 10, 14 and 18 days. After 14 days we observed satisfactory healing and the best conditions for soft tissue dissection. This was in accordance with a tendon-to-bone healing study demonstrating that the tendon was attached securely within the bone tunnel after 14 days \(^{25}\). Time studies would of course have been of great interest to elucidate if the impaired healing was transient and the healing would be restored in the long term. Our main aim was to elucidate if the healing was impaired at an early time point as this might have a direct impact on patient mobilization after reconstructions using tendon grafts in bone tunnels. The Achilles tendon was dissected free from the calf muscle proximally and all muscle fibers were removed from the tendon. The tendon was then pulled through a 2 mm drill hole in distal tibia and secured anteriorly to the perios-teum with a suture with the ankle joint held in 90 degrees. The animals were allowed full weight on their injured legs, with no immobilization. Therefore, the tendon was put under tension during mobilization. After 14 days the Achilles tendons were meticulously dissected free from the bone. The only remaining contact between tendon and bone was inside the drill hole. This was probably the most crucial point in the surgical procedure. 2 tendons from each group slipped out during the dissection, probably due to improper healing of the tendon in the bone tunnel. These specimens were excluded.

BMD measurements
Lunar PIXIUS (Lunar, Madison, Wisconsin, USA) is specially designed for BMD measurements on small animals using Dual Energy X-ray Absorptiometry (DEXA). By using this method, we were able to measure BMD at the fracture site on anesthetized animals at different time points during healing. The intramedullary nail had to be included in the measurements, but its constant value was subtracted from the calculated BMD values to estimate the real BMD at the fracture site. As the intramedullary nail was included in the measurements, the real difference in BMD in the fracture callus was probably larger than observed, since the nail represented an equal constant in all groups. To validate this method, we also measured BMD after killing and removal of the nail, and this showed equal results indicating that the DEXA measurement with the nail in place was a reliable method. In Paper I the BMD after treatment with parecoxib at 0.05 mg/100 g body weight did not differ significantly from placebo after 3 weeks (p < 0.06) in contrast with the results from Paper II where animals treated with the same dose of parecoxib, for the same period of time did show difference in BMD values when compared with the placebo group. However, in both studies, the values were borderline significant values, one just over and the other one just below a p-value of 0.05. Our first study was possibly underpowered, explaining the difference between the results in the two Papers. Furthermore, we used animals from two different producers and strains in these two studies, this may also have contributed to the small differences in BMD.

Mechanical bone testing
In study I and II a three-point cantilever bending test was used. The test was originally developed for the rat femoral shaft \(^{170}\), but has been modified for tibial shaft testing \(^{152}\). This test has recently been modified again by incorporating the three-point cantilever bending test apparatus in an MTS machine (Model 858 Minin Bionix with Test Star II controller, MTS Systems,
Four-point bending tests or torsional tests are often used for mechanical testing of the soft callus due to concerns related to possible deformation of the soft callus from the fulcrum in three-point bending. However, in our three-point bending test, the distal tibia is fixed, and the proximal fragment is bent in an anterior direction, so that the fulcrum is not moving or sagging into the callus. The three-point bending test gains standardized fractures and reliable results, and have been used by our group in several previous studies published in peer-reviewed journals.

Both the fractured right tibia and the intact left tibia were fractured and the bending moment, total energy, deflection and bending stiffness were registered and calculated. The ratios between the right and the left tibia for the four mechanical properties were calculated.

The bending moment is the ultimate load the bone can withstand before fracture (top point of the gray load-displacement curve) multiplied by the moment arm by which the load is applied in the MTS machine. The total energy is the energy absorbed by the bone until fracture (the area under the curve until failure excluded the preloading). Deflection is the ultimate deformation in the bending of the bone before fracture (the point on the displacement axis corresponding to the fracture point). Stiffness is the ratio of the applied bending moment on the corresponding deflection in the straight, elastic part of the load-displacement curve (the black line).

**Mechanical tendon testing**

In Paper III a stretching test aligned parallel with the tendon was performed. The proximal tendon was spread like a fan and clamped between fine grained sand paper, and the calcaneus was held in a claw. No healing tendons slipped in the clamp during testing, but when testing intact tendons, they slipped out of the clamp before rupturing. Thus, ratios could not be compared like in studies I and II. The tensile strength (stretching force), total energy, deflection and stretching stiffness were registered.

Tensile strength was the ultimate load the tendon could withstand before rupture. Total energy was the energy absorbed by the tendon until rupture. Deflection was the ultimate stretching of the tendon before rupture. Stiffness was the ratio of the applied force on the corresponding deflection in the straight, elastic part of the load-displacement curve (black line).

**Mechanical tendon-to-bone testing**

In Paper IV a pull out test was performed. The calcaneus was held in the same claw as in Paper III, while the tibia was fixed in a custom made metal clamp. This clamp ensured that the drill hole was aligned with the direction of the force applied, and there was no contact between the tendon and the metal clamp. The ultimate pull out strength, total energy, deflection pullout and stiffness were registered.

Pullout strength was the ultimate load that the tendon-to-bone junction could withstand before failure. Total energy was the energy absorbed by the tendon-to-bone interface until failure. Deflection was the ultimate stretching of the tendon-to-bone interface before failure. Stretching stiffness was the ratio of the applied force on the corresponding deflection in the straight, elastic part of the load-displacement curve (black line).

**Statistical analysis**

All the mechanical data were registered in TestStar software (MTS Systems, Corporation Eden Prairie, Minnesota, USA)
and calculations were made in SPSS for Macintosh (SPSS Inc., Chicago, Illinois, USA). Statistical significance was set at \( p < 0.05 \).

In Paper I, the two groups were compared by an unpaired Students t-test. For the DEXA measurements Bonferroni adjustment for multiple time-point tests were applied.

In Paper II–IV the three groups were compared using Analysis of Variance (ANOVA). Scheffe’s post hoc test \(^{171}\) was chosen to demonstrate if there was a negative effect of parecoxib and indomethacin on healing to give maximum protection against type I errors.
Results

In these studies we demonstrated that cox inhibitors reduced the BMD and impaired the mechanical strength in healing fractures. Tendon healing and tendon-to-bone healing were also impaired.

From our studies, and previous studies published on this topic, there should be no doubt about the cox inhibitors negative effect on the healing process. However, there are numerous uncertainties connected to the degree of significance for tissue healing in humans.

One of the important questions concerning cox inhibitors’ effect on tissue healing is whether short-term administration of these drugs in relation to surgery or injury only temporarily delay the healing or definitely influence the final outcome.

In study I we demonstrated that parecoxib exerted an inhibitory effect on the mineralization of fracture callus, but the study suggested that the effect was temporary. The difference between BMD in the two groups was largest after 2 weeks, and after 6 weeks there were no significant differences. In study II we demonstrated similar results; the difference between BMD in animals administered indomethacin and the placebo group was largest after 2 weeks, but there were no significant differences after 3 weeks. Comparable results have been demonstrated in other studies using radiological analysis or radiological bone density calculations, even though the duration of drug administration differed in the groups they compared. Fractures in animals administered cox inhibitors for a short time period had better radiological signs of healing compared to animals administered cox inhibitors for a longer period.

Concerning mechanical testing we did not find differences when testing after 6 weeks in study I. However, when testing earlier in the healing period (3 weeks, study II), there was a significantly decreased strength in animals administered both parecoxib and indomethacin compared to the placebo group. This also indicates that when administering cox inhibitors short-term only, the negative effects are reversible. Corresponding findings are seen in other studies. Histologically, significantly more fibrous tissue and less woven bone formation were found after 4 and 8 weeks, but not after 12 weeks. Initiating cox inhibitor treatment in the later course of fracture healing may also have a negative effect on the healing process, but not to the same extent as when treatment is administered around the time of fracture.

Thus, short-term administration of cox inhibitors delays fracture healing, but the healing process is probably restored when inhibition is removed.

Tendon healing is different from bone healing. In Paper III we demonstrated impaired tendon healing after short-term administration of parecoxib or indomethacin. It has previously been suggested that cox inhibitors might have a negative effect on the proliferative phase of tendon healing, but might have a positive effect in the remodeling phase. Accordingly it is demonstrated that inflammation appears to have a negative influence during remodeling. Long term application of cox inhibitors are reported to increase the failure stress in a healing tendon when administered until trial termination, i.e. during both the proliferative phase and the remodeling phase.

In Paper III the cox inhibitors were administered in the early phase only. Due to this, the proliferation phase was inhibited, and healing was impaired.

Consequently, short-term cox inhibitor administration delay tendon healing. However, administered in the later phase of healing cox inhibitors might be beneficial.

Tendon-to-bone healing is also different from both fracture healing and tendon healing. However, like in fractures and tendon injuries, the healing process is initiated with an inflammatory phase. In Paper IV we demonstrated that short-term administration of parecoxib and indomethacin impaired tendon-to-bone healing.

In Ferry’s study they administered the drugs until termination after 2 weeks, and patellar tendon-to-bone healing strength was decreased by the cox-2 inhibitors celecoxib and valdecoxib, and also by the conventional NSAID piroxicam, but not by naproxen and ibuprofen. Collagen content at the repair site was decreased for all but ibuprofen. The differences between the cox inhibitors were probably due to inadequate dosages or different metabolism of the drugs. In Cohen’s study they administered the drugs for 2 weeks, and demonstrated significantly lower failure loads in rotator cuff sutures after 2, 4 and 8 weeks in rats administered celecoxib or indomethacin, when compared to the placebo. The differences persisted at 8 weeks, and in contrast to findings in fracture healing, there was no indication that the impairment of tendon-to-bone healing was temporary. Thus, regarding tendon-to-bone healing, short-term administration impairs healing. It remains unclear whether the negative effects of cox inhibitors on tendon-to-bone healing are transient or persistent.

Another important question is whether inhibition of cox-1 or cox-2 is responsible for the negative effects on the healing process.

The cox-2 enzyme is inducible and involved in producing PGs related to acute inflammations, while the cox-1 enzyme is produced constitutively and involved in the homeostatic regulation. Therefore, one would expect that the inducible cox-2 was the enzyme involved in the healing process. In a study using mice genetically deficient for cox-1 or cox-2 enzyme, it was demonstrated that cox-2 is critically involved in bone repair and required for both intramembranous and endochondral bone formation. In another study using these mice, and also rats,
administered both conventional cox inhibitors and cox-2 inhibitors, they also demonstrated that cox-2 function was specifically essential for fracture healing. Several other studies have also demonstrated that cox-2 inhibitors impair fracture healing. Furthermore, cox-2 plays an essential role in osseointegration of implants, and inhibits rotator cuff tendon-to-bone healing in rats. Cox-2 activity is also crucial during the early stages of muscle regeneration; muscle regeneration was attenuated by a cox-2 inhibitor but was unaffected by cox-1 inhibition, and cox-2 inhibition resulted in fewer myoblasts. Cox-2 also regulates growth of atrophied muscle.

In fracture calluses in rats, cox-2 mRNA levels showed peak expression during the first 2 weeks of healing in rats and returned to basal levels by 3 weeks. Accordingly, PGE$_2$ reached the highest levels 24 hours after fracture and declined to baseline by 35 days. The PGE$_2$ levels in the callus were reduced when cox inhibitors were administered to the animals. PGE$_2$ was the first PG shown to influence bone metabolism, and a PGE$_2$ agonist specifically promoted fracture healing. PGE$_2$ has been assumed to be the major product of cox-2 activity and being the primary mediator of the anabolic activities in skeletal cells. Furthermore, cox-2 is induced early in response to muscle injury, and mRNA levels peak 4 days after injury.

In the present thesis, the specific cox-2 inhibitor parecoxib showed a more pronounced negative effect on fracture healing, tendon healing and tendon-to-bone healing compared to the conventional NSAID indomethacin. This is in accordance with findings reported in the literature in general. Considering findings in earlier published studies, we expected to find impaired healing in rats administered indomethacin in human doses adjusted for weight in rats. We hypothesized that even more reduced healing in rats administered parecoxib in human doses would argue for inhibition of cox-2 to be the responsible mechanism. However, due to uncertainties related to the metabolism of different NSAIDs and cox-2 inhibitors in rats, we cannot conclude that cox-2 inhibition is responsible for the impaired healing. Altogether, however, findings indicate that cox-2 is the enzyme responsible for initiating the healing process and that inhibition of cox-2 is responsible for the impaired healing. Due to this, inhibition of cox-2 during the early period after injury or surgery seems to have the most detrimental effects on tissue healing.

Impaired healing on the basis of cox inhibition is probably not due to inhibition of the inflammation alone. Several mechanisms are most likely involved. PGs are synthesized in the inflammatory process, and are important to initiate bone healing. PGs also play an important role in regulating bone metabolism and preventing an imbalance between bone resorption and bone formation. When a cox-2 inhibitor was administered 2 weeks after fracture, a negative effect on healing was still observed. This suggests that cox-2 might have additional functions during fracture healing besides inhibiting PGs.

Angiogenesis is essential for successful fracture healing and endochondral ossification. Angiogenesis is also shown to be inhibited by cox-2 inhibitors, and vascularization of fracture callus in mice genetically deficient for cox-2 is reported to be reduced. This might lead to improper delivery of osteclasts and osteoblasts to the fracture area. Corresponding mechanisms are seen after muscle injury where the intramuscular number of inflammatory cells as macrophages are decreased. Muscle regeneration is impaired when inflammatory cells are depleted and stimulated when they are increased. Macrophages are necessary in the repair process to phagocytose cellular debris and secrete growth factors, cytokines and PGs that are implicated in myogenesis. The majority of macrophages in injured muscle are claimed to invade from circulation and are not a result of the proliferation of resident macrophages. Therefore, impaired release of vasodilatory PGs by cox-2 inhibition might also lead to improper delivery of inflammatory cells to the injury site, not only in muscle, but in tendon and bone as well.

Bone morphogenetic proteins (BMPs), which are important regulators of bone formation, might also be affected by cox inhibition. In a study using bone marrow stromal cell cultures obtained from mice genetically deficient for cox-2, findings suggested that reduced PGE$_2$ level due to cox-2 inhibition interfere with BMP-2 signaling events leading to reduced levels of 2 genes necessary for bone formation. Another study demonstrated similar findings where the expression of BMP-7 was increased upon PGE$_2$ treatment. Also concerning tendon healing, and probably tendon-to-bone healing, these mechanisms might be present as BMPs, and may be necessary for normal repair. Other BMPs, like the cartilage-derived morphogenic proteins (CDMPs) is demonstrated to improve early tendon healing, and reduced PGE$_2$ due to cox inhibition, might interfere with CDMP-2 signaling.

It is also shown that mice, genetically deficient for cox-2, have elevated plasma levels of both Ca$^{2+}$ and PTH consistent with primary hyperparathyroidism, suggesting that the cox enzymes are regulators of BMD and bone strength. The same study demonstrates lower BMD, decreased bone strength and decreased trabecular volume in mice genetically deficient for cox-2.

In summary, findings from different studies indicates that fracture healing, tendon healing and tendon-to-bone healing, regulated through the cox-2 pathway, involve multiple mechanisms, not only the inhibition of inflammation.

Altogether, short-term administration of cox inhibitors impairs the healing process in bone and tendons. Administered in doses equivalent to human doses, the inhibition is more pronounced with cox-2 inhibition than with cox-1 inhibition.

Clinical considerations

An important question concerning cox inhibitors and tissue...
healing in relation to this thesis is the clinical relevance of the findings; results of experimental animal studies cannot be directly extrapolated to the human clinical setting. However, as long as experimental studies demonstrate that cox inhibitors are potentially deleterious to healing of bone, tendon and tendon-to-bone, these studies should be our guidance and make clinicians aware of the possible deleterious effects on musculoskeletal tissue healing of these drugs.

Aspenberg asserted in an Editorial in 2002 that cox inhibitors should be avoided after skeletal surgery. Few studies have been published since that would cause one to change this view. However, cox inhibitors could probably be considered for administration after fractures that usually incur few or no healing problems, like distal radial fractures and acetabular fractures. This is in accordance with findings in Burd’s study were 29% of patients administered indomethacin had a non-union of a long bone fracture, but all acetabular fractures in the same patients healed. Concerning arthroplasties, it has recently been demonstrated that administration of cox inhibitors to patients after implantation of cemented knee prostheses did not affect the outcome after 2 years. It is likely that cox inhibitors can be administered when implanting cemented prostheses, where bone ingrowth into the implant is not required. One should be aware, however, of a possibly elevated risk of infections. In a prospective randomized study on patients undergoing coronary artery bypass surgery, there was an increased incidence of sternal wound infections in patients administered cox-2 inhibitors compared to the placebo. Considered the severity infected arthroplasties in particular, and deep infections in relation to orthopedic surgery in general, it is important to elucidate if cox inhibitors have an effect on wound healing and wound infections.

No prospective randomized clinical trial on long bone fractures with or without cox inhibitor treatment have been performed. However, an association between the use of NSAIDs after injury and nonunion in human has been observed for femoral shaft fractures in retrospective studies. This supports the findings from a large number of experimental studies. It is not unlikely that these findings also apply to all human fractures known to be vulnerable to nonunion and delayed union and other similar bone healing situations. Although the negative effect of short-term administration of cox inhibitors on fracture healing seems to be transient in the experimental studies, this might not be the case in humans, as the fracture healing potential is much better in rats compared to humans.

Concerning soft tissue healing in a clinical setting, cox inhibitors are widely used for sports related injuries and after surgery. Lately, however, concerns also have been expressed regarding the treatment of muscle, ligament and tendon injuries as long as they might be potentially deleterious to tissue healing. Prospective randomized clinical trials have not been performed in terms of tendon or tendon-to-bone healing. Based on experimental studies, however, cox inhibitors should probably be avoided in the proliferation phase, but might be considered for administration in the later remodeling phase during soft tissue healing in tendons and ligaments. Furthermore, after procedures requiring tendon-to-bone healing like rotator cuff repairs, tendon reinsertions and cruciate ligament reconstructions cox inhibitors should probably be avoided altogether.

There are still numerous unknown aspects of the use of cox inhibitors. The negative effects on healing of musculoskeletal tissue demonstrated in experimental studies should be thoroughly elucidated in clinical studies before cox inhibitors are administered to these patients.